Hot on the trail of "I know it when I see it!"

Affiliations

Editorial

Jerome Parness. Anesth Analg. 2014 Feb.

. 2014 Feb;118(2):243-246.

doi: 10.1213/ANE.0000000000000064.

¹ From the Department of Anesthesiology, University of Pittsburgh School of Medicine, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania.

No abstract available

Comment on

Malignant hyperthermia in Canada: characteristics of index anesthetics in 129 malignant hyperthermia susceptible probands.
Riazi S, Larach MG, Hu C, Wijeysundera D, Massey C, Kraeva N. Riazi S, et al. Anesth Analg. 2014 Feb;118(2):381-387. doi: 10.1213/ANE.0b013e3182937d8b. Anesth Analg. 2014. PMID: 23842196

1. Nelson P, Litman RS. Malignant hyperthermia in children: an analysis of the North American Malignant Hyperthermia Registry. Anesth Analg. 2014;118:369–74
1. Visoiu M, Young MC, Wieland K, Brandom BW. Anesthetic drugs and onset of malignant hyperthermia. Anesth Analg. 2014;118:388–96
1. Parness J, Bandschapp O, Girard T. The myotonias and susceptibility to malignant hyperthermia. Anesth Analg. 2009;109:1054–64
1. Lanner JT, Georgiou DK, Joshi AD, Hamilton SL. Ryanodine receptors: structure, expression, molecular details, and function in calcium release. Cold Spring Harb Perspect Biol. 2010;2:a003996
1. Hopkins PM. Malignant hyperthermia: pharmacology of triggering. Br J Anaesth. 2011;107:48–56